228246-75-1

Usage

Uses

Used in Pharmaceutical Development:
(R)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE is used as a building block in the synthesis of biologically active compounds for the development of pharmaceutical drugs. Its unique structure and functional groups contribute to the creation of potential drug candidates for the treatment of various diseases and medical conditions.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE serves as a valuable compound for research and development. Its chiral nature and complex structure make it an interesting subject for studying pharmacological properties and exploring its potential therapeutic uses.
However, it is important to note that further research and development are needed to fully understand the pharmacological properties and potential therapeutic uses of (R)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE in various applications.

InChI:InChI=1/C17H17NO/c19-14-7-9-18(10-8-14)16-11-13-5-1-3-12-4-2-6-15(16)17(12)13/h1-6,16H,7-11H2/t16-/m1/s1

Upstream product

• 2235-15-6 1(2H)-acenaphthylenone 
• 1238893-65-6 (R)-(acenaphthen-1-yl)amine hydrochloride 
• 86-87-3 naphth-1-yl acetic acid 
• 5121-00-6 naphthalen-1-yl-acetyl chloride 
• 121961-98-6 (S)-(+)-1,2-dihydroacenaphthylen-1-ol 
• 77542-18-8 1-methyl-1-ethyl-4-oxopiperidinium iodide 
• 228246-73-9 (R)-1-Acenaphthylamine 

Downstream Products

• 228246-77-3 (R)-4-phenylamino-1-(acenaphthen-1-yl)-piperidine4-carbonitrile 

Relevant academic research and scientific papers

REMEDY FOR SLEEP DISTURBANCE

The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more particularly, an agent for the prophylaxis and/or treatment of a sleep disorder, which contains an ORL-1 receptor agonist, and a novel compound useful as such agent for the prophylaxis and/or treatment.

1,3,8-triazaspiro[4,5]decan-4-one derivatives

The present invention relates to compounds of the formula wherein R1 and R2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen; R3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF3, lower alkoxy or halogen; R4 is hydrogen, lower alkyl, lower alkenyl, -C(O)-lower alkyl, -C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF3, phenyl or benzyl, R5 and R6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R5 and R6 together with the carbon atoms to which they are bound form a phenyl ring, or R5 and one of R1 or R2 together with the carbon atoms to which they are bound form a saturated or unsaturated 6 membered ring, A is a 4-7 membered saturated ring, their racemates and the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof which are agonists and/or antagonists of the OFQ receptor.

8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists

A series of 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4- one derivatives 1 was studied with respect to the binding affinity for the orphanin FQ (OFQ) and opioid (μ, κ, δ) receptors. The influence of stereochemistry as well as the substitution pattern of the phenyl-ring in position 1 on the affinity for the orphanin FQ receptor and selectivity to opioid (μ, κ, δ) receptors is discussed. The most interesting compound 1c was tested for its anxiolytic-like properties in vivo.